Pilot Study on the Feasibility of High-energy Collimation With Optimized Geometry on a VERITON™ CZT Camera

NCT07572318 | Not Yet Recruiting

• 1 other identifier: 2026-A00456-45
• Study Type: interventional
• Target: 18
• Locations: 0 countries
• Sites: N/A

Brief Summary

Functional imaging using scintigraphy plays a major role in the diagnosis and monitoring of many diseases, particularly thanks to its ability to perform whole-body examinations with high contrast. The indications and use of scintigraphy have increased in recent years, particularly in connection with the development of internal vectorized radiotherapy. This therapeutic approach is based on the administration of radiotracers that enable targeted irradiation of tumor cells, whose biodistribution throughout the body can be analyzed and quantified using scintigraphy, particularly with iodine-131 and lutetium-177. The recent boom in scintigraphy is also linked to the development of new 360° geometry CZT-SPECT cameras, which enable rapid tomographic acquisitions of the entire body with significantly improved image quality compared to conventional cameras. These systems use mobile CZT semiconductor detectors that dynamically scan the anatomical regions of interest. CZT detectors are combined with a collimation system consisting of tungsten septa, which are essential for the directional filtering of gamma photons. Unlike conventional scintigraphic cameras, where collimators can be changed or adjusted according to the energy of the detected photons, CZT-SPECT 360° cameras generally rely on fixed collimation, which cannot be changed.

Conditions

Cancer

Keywords

scintigraphy; scintigraphy post therapeutic

Outcome Measures

Primary Outcomes (2)

• Feasability of whole-body SPECT/CT imaging with iodine-131 using the optimized collimator

  Data analysis obtained with optimized collimator and with conventional collimator

  1 month

• Perform quantitative analysis of technetium-99m and lutetium-177 with feasability results

  Image sharpness improvment

  1 month

Secondary Outcomes (2)

• Overall quality of whole-body CZT acquisitions with iodine-131

  1 month

• Quantify the detectability and contrast of lesions visualized on whole-body CZT imaging with iodine-131.

  1 month

Study Arms (2)

VERITON-CT New

EXPERIMENTAL

Optimized collimators for the CZT detectors of the VERITON™ 400 wide-field camera (Spectrum Dynamics Medical) enabling better selection of incident photons

Device: Scintigraphy VERITON with new collimator

Référence

ACTIVE COMPARATOR

* Full-body 3D recording on the VERITON™ 400 camera equipped with conventional collimators for technetium-99m and lutetium-177. * 2D whole-body and 3D cervicothoracic recordings on an Anger camera (SYMBIA camera, Siemens Healthineers) for iodine-131 images.

Device: Scintigraphy VERITON; Device: Scintigraphy SYMBIA

Interventions

Scintigraphy VERITON DEVICE

Full-body 3D recording on the VERITON™ 400 camera

Référence

Scintigraphy VERITON with new collimator DEVICE

\- Whole-body 3D recording on the VERITON™ 400 camera equipped with conventional collimators for technetium-99m and lutetium-177.

VERITON-CT New

Scintigraphy SYMBIA DEVICE

Whole-body 2D and cervicothoracic 3D recordings using an Anger camera (SYMBIA camera, Siemens Healthineers) for iodine-131 images.

Référence

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• patients with multiple known lesions (≥ 2 metastases or lesions of other types) who, as part of their clinical management, require either (i) a 99mTc-HDP bone scan, or (ii) a post-therapeutic 177Lu-PSMA scan, or (iii) a post-therapeutic 131I scintigraphy.
• Person who has undergone a preliminary clinical examination appropriate for clinical research.
• Adult subject who has received complete information about the research and has signed the informed consent form.
• General condition, WHO ≤ 2, and ability to remain lying down without moving for nearly an hour.

You may not qualify if:

• Subjects with a contraindication, according to the target examination group, to injection of 99mTc-HDP (Technescan HDP, Curium Pharma), 177Lu-PSMA (Pluvicto®, Novartis), or 131I (131I sodium iodide for therapy, Curium Pharma) .
• Subjects covered by Articles L. 1121-5, L. 1121-7, and L1121-8 of the Public Health Code.
• Pregnant women, women in labor, or breastfeeding mothers.
• Subjects subject to legal protection measures (guardianship, curatorship, judicial protection).
• Subjects unable to give their consent.
• Subjects deprived of their liberty by a judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L.3213-1.

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

MeSH Terms

Conditions

Neoplasms

Central Study Contacts

Anne-Sophie Hue Project Manager, MSc

CONTACT

+33.3.83.15.34.75; a.hue@chru-nancy.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Prinicipal Investigator

Study Record Dates

• First Submitted: February 24, 2026
• First Posted: May 7, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): May 1, 2027
• Last Updated: May 7, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share